For our 77th episode, we discuss a study in the Journal of Clinical Endocrinology & Metabolism investigating the role of immune signaling in polycystic ovary syndrome (PCOS), now renamed polyendocrine metabolic ovarian syndrome (PMOS). Using a multiracial case-control design, the authors examined whether PCOS is characterized by chronic inflammation or whether immune dysregulation plays a more central role in its pathophysiology.Host Chase Hendrickson, MD, MPH, MHCC, from Vanderbilt Health, is joined by regular contributor Anna Goldman, MD, from Harvard Medical School, Brigham and Women's Hospital, and Atrius Health, along with guest expert Corrine Welt, MD, Chief of Endocrinology at the University of Utah, to discuss "Multiracial Cytokine Profiling Reveals Immune Dysregulation not Chronic Inflammation in Polycystic Ovary Syndrome." Together, they explore the implications of the syndrome's recent name change, review the study's unexpected findings of lower circulating inflammatory markers in women with PCOS, and discuss the challenges of disentangling the effects of adiposity, metabolism, and immune function. The conversation highlights what these results reveal about the evolving understanding of PCOS and whether they have implications for current clinical practice.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related